Compare AbCellera Biologics Inc (ABCL) vs M&T Bank Corporation (MTB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs M&T Bank Corporation — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while M&T Bank Corporation trades at $233.96 (market cap $35.11B). The key difference: M&T Bank Corporation is far larger — about 14.9× AbCellera Biologics Inc's market cap, and M&T Bank Corporation pays a 2.5% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MTB | |
|---|---|---|
Market Cap | $2.35B | $35.11B |
Sector | Health | Financials |
52-Week High | $8.12 | $241.95 |
52-Week Low | $2.78 | $178.63 |
Enterprise Value | $1.99B | — |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
MTB trades at $239.75, up 0.36% today, near the consensus price target of $241.56. The stock shows a bullish technical trend with consistent earnings beats in recent quarters. Revenue grew to $9.63B in 2025, with a strong net income margin of 29.59%. Recent news highlights upcoming Q2 2026 earnings and strategic leadership appointments, reinforcing operational focus.
The outlook is cautiously positive, supported by solid fundamentals and analyst consensus, but risks include elevated investing cash outflows and sensitivity to interest rate changes. The stock presents a value opportunity with a reasonable P/E of 13.47, though investor sentiment remains mixed ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
